

Eamonn Hobbs Bio

Eamonn Hobbs has had tremendous success in creating long lasting innovative endeavors and growing them into strong financially performing companies. His greatest achievement to date was AngioDynamics, Inc. which he founded as a division of a public parent company, E-Z-EM, Inc. (NASDAQ: EZEM), and lead it through a value-creating carve out tax-free spin-off and simultaneous IPO, (NASDAQ: ANGO). AngioDynamics, Inc. became the best performing med-tech IPO of 2004, and continued to demonstrate award winning performance throughout Mr. Hobbs tenure.

In 2004 Mr. Hobbs was provided with extraordinary recognition by being granted an Honorary Fellowship by the Society of Interventional Radiology (SIR), receiving one of ten Honorary Fellowships granted in the 50-year history of the SIR, and one of only three ever granted to a non-physician.

He has extensive expertise in financing, acquisitions & integrations, scaling operations and commercialization success in heavily entrenched markets.

Since leaving AngioDynamics in 2009 Mr. Hobbs has served on many public and private company Boards, two of which asked him to become CEO. He currently serves on the Board of OraSure Technologies (NASDAQ: OSUR), a leader in the field of oral sample diagnostics products, Harmonic Medical, Inc., a Toronto based private company developing the world's first ultrasound guided HIFU (high intensity focused ultrasound) with an initial application for physician office based fibroid ablations, and is Chairman of the Board of Marvao Medical, a Galway, Ireland based company developing NexSite, a new technology that materially reduces CRBSI (Catheter Related Blood Stream Infections) in long term indwelling vascular access catheters.

In October of 2016, Mr. Hobbs was appointed as Visiting Scholar, Lecturer and Expert in Residence at the Translational Accelerator of Brigham and Women's Hospital, the teaching hospital of Harvard Medical School. The mission of the Translational Accelerator is to provide scientists the necessary tools, training, and resources to facilitate and accelerate the translation of inventions with potential commercial value from bench to bedside. He is involved in advising, training and mentoring of physician scientist inventors affiliated with the Brigham and Women's Hospital and Harvard Medical School and assist the physician scientists in advancing their inventions and efficiently increasing their commercial value.

In January of 2018, Mr. Hobbs co-founded and became Chairman and CEO of ImmunSYS, Inc., a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with metastatic prostate cancer and other metastatic solid tumors. The company's platform technology is designed to empower the immune system to recognize and selectively attack cancer throughout the body.

Since 2013 to present, Mr. Hobbs leverages his 40 years of experience as President of Hobbs Medical Ventures, a boutique consulting firm that provides wide-ranging solutions for the biotech, pharma and medical device industries. Some of the firm's specialties include market and technology assessment, new product planning, corporate strategy, executive mentoring, corporate brand planning and M&A due diligence.

Mr. Hobbs has extensive experience in medical devices, pharmaceuticals, drug delivery technology and combination drug/device products, including taking them from inception through very successful commercialization. He is very strategic in his thinking and prides himself on developing top performing business plans and leadership teams through collaboration, communication and empowerment. Mr. Hobbs was elected twice by his industry leadership peers to be Chairman of the Medical Device Manufacturers Association (MDMA), and in that role built strong and collaborative relationships with government and regulatory leaders to help advance improvements in patient care through our industry working to advance innovation.